5 stories mentioning NSE:DRREDDYUpdated 3m ago
Every FINWIRES story that references NSE:DRREDDY, newest first.
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has an average rating of hold and mean price target of 1,335.44 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Dr. Reddy's Laboratories' (NSE:DRREDDY) consolidated attributable profit plunged to 2.21 billion Indian rupees in the fiscal fourth quarter ended March 31, from 15.9 billion rupees a year ago.Earnings per share contracted to 2.64 rupees from 19.11 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Tuesday. The EPS was much lower than the 10.45 rupees estimated by the analysts polled by Visible Alpha.Revenue in fiscal Q4 also slipped to 75.2 billion rupees from 85.1 billion rupees a year ago. This was also lower than Visible Alpha's estimate of 81.6 billion rupees.The company's board recommended a final dividend of 8 rupees per equity share of face value of 1 rupee each for the financial year 2025-26. The record date to determine the members eligible to receive the dividend has been fixed as July 10.
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, the Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/pen (in 1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).Dr. Reddy's shares were down nearly 1% in recent trade.
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).The company's shares were down nearly 1% in recent trade.
Dr. Reddy's Laboratories' (NSE:DRREDDY, BOM:500124) board will meet on May 12 to consider the payment of a final dividend for fiscal 2026 ended March 31, according to an Indian bourse filing on Thursday.
